Vista, CA, United States of America

John Charles Arthur

USPTO Granted Patents = 9 

Average Co-Inventor Count = 6.4

ph-index = 5

Forward Citations = 64(Granted Patents)


Location History:

  • La Jolla, CA (US) (2019)
  • North Wales, PA (US) (2021)
  • Vista, CA (US) (2016 - 2023)

Company Filing History:


Years Active: 2016-2023

Loading Chart...
9 patents (USPTO):

Title: Innovations of John Charles Arthur

Introduction

John Charles Arthur is a notable inventor based in Vista, CA (US). He has made significant contributions to the field of pharmaceuticals, holding a total of 9 patents. His work primarily focuses on developing new compositions and methods for treating chronic hyperkinetic movement disorders.

Latest Patents

One of his latest patents is titled "Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2." This invention relates to new pharmaceutical compositions comprising benzoquinoline compounds. The methods described aim to inhibit vesicular monoamine transporter 2 (VMAT2) activity in a subject, providing potential treatment options for chronic hyperkinetic movement disorders.

Career Highlights

John Charles Arthur has established himself as a key figure in the pharmaceutical industry. His innovative approaches and research have led to advancements in the treatment of movement disorders. He is currently associated with Auspex Pharmaceuticals, Inc., where he continues to contribute to the development of groundbreaking therapies.

Collaborations

Throughout his career, John has collaborated with notable colleagues, including Andreas Sommer and Chengzhi Zhang. These partnerships have enhanced his research and expanded the impact of his inventions.

Conclusion

John Charles Arthur's work exemplifies the spirit of innovation in the pharmaceutical field. His contributions are paving the way for new treatments that can significantly improve the quality of life for individuals with movement disorders.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…